Gene test may personalize heart drug dosing
NCT ID NCT07439952
First seen Mar 19, 2026 · Last updated Jun 09, 2026 · Updated 12 times
Summary
This study looks at how a person's genes affect their response to the heart drug mavacamten for obstructive hypertrophic cardiomyopathy. Researchers will collect DNA samples from 300 patients to see which genetic types respond best. The goal is to improve dosing safety and effectiveness based on genetic differences.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHP, Ambroise Paré
Boulogne-Billancourt, 92100, France
Contact
Contact Email: •••••@•••••
-
APHP, Bicêtre hospital
Le Kremlin-Bicêtre, France
Contact Email: •••••@•••••
Contact
-
APHP, La Pitié Salpetriere hospital
Paris, 75013, France
Contact Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.